20 studies found for:    ataluren
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Enrolling by invitation Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Conditions: Muscular Dystrophy, Duchenne;   Muscular Dystrophies;   Muscular Disorders, Atrophic;   Muscular Diseases;   Musculoskeletal Diseases;   Neuromuscular Diseases;   Nervous System Diseases;   Genetic Diseases, X-Linked;   Genetic Diseases, Inborn
Intervention: Drug: Ataluren
2 Terminated Phase 2b Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)
Conditions: Duchenne Muscular Dystrophy;   Becker Muscular Dystrophy
Intervention: Drug: Ataluren (PTC124)
3 Active, not recruiting Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
Conditions: Muscular Dystrophy, Duchenne;   Muscular Dystrophies;   Muscular Disorders, Atrophic;   Muscular Diseases;   Musculoskeletal Diseases;   Neuromuscular Diseases;   Nervous System Diseases;   Genetic Diseases, X-Linked;   Genetic Diseases, Inborn
Interventions: Drug: Ataluren;   Drug: Placebo
4 Terminated Study of Ataluren (PTC124®) in Nonambulatory Patients With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD)
Conditions: Duchenne Muscular Dystrophy;   Becker Muscular Dystrophy
Intervention: Drug: Ataluren (PTC124)
5 Terminated Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: Ataluren
6 Completed Study of Ataluren (PTC124™) in Cystic Fibrosis
Condition: Cystic Fibrosis
Interventions: Drug: Ataluren (PTC124);   Drug: Placebo
7 Enrolling by invitation Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and Canada
Conditions: Duchenne Muscular Dystrophy;   Becker Muscular Dystrophy;   Dystrophinopathy
Intervention: Drug: Ataluren
8 Active, not recruiting Extension Study of Ataluren (PTC124) in Cystic Fibrosis
Condition: Cystic Fibrosis
Intervention: Drug: Ataluren (PTC124)
9 Suspended Study of Ataluren (PTC124®) in Hemophilia A and B
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: Ataluren (PTC124)
10 Completed Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (DMD/BMD)
Conditions: Duchenne Muscular Dystrophy;   Becker Muscular Dystrophy
Intervention: Drug: PTC124
11 Suspended Ataluren for Nonsense Mutation Methylmalonic Acidemia
Condition: Amino Acid Metabolism, Inborn Errors
Intervention: Drug: Ataluren (PTC124)
12 Enrolling by invitation Study of Ataluren (PTC124®) in Cystic Fibrosis
Condition: Cystic Fibrosis
Intervention: Drug: Ataluren (PTC124®)
13 Enrolling by invitation Study of Ataluren for Previously Treated Patients With nmDBMD in the US
Conditions: Duchenne Muscular Dystrophy;   Becker Muscular Dystrophy
Intervention: Drug: Ataluren
14 Completed PTC124 for the Treatment of Cystic Fibrosis
Condition: Cystic Fibrosis
Intervention: Drug: PTC124
15 Recruiting Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)
Condition: Cystic Fibrosis
Interventions: Drug: Ataluren (PTC124®);   Drug: Placebo
16 Completed PTC124 for Cystic Fibrosis
Condition: Cystic Fibrosis
Intervention: Drug: PTC124
17 Completed PTC124 for Pediatric Patients With Cystic Fibrosis
Condition: Cystic Fibrosis
Intervention: Drug: PTC124
18 Completed Safety and Efficacy of PTC124 for Cystic Fibrosis
Condition: Cystic Fibrosis
Intervention: Drug: PTC124
19 Completed Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: PTC124
20 Completed The PTC124 (Ataluren) Clinical Trial for Duchenne Muscular Dystrophy: Exploration of the Experiences of Parents, Clinician Researchers, and the Industry Sponsor
Condition: Duchenne Muscular Dystrophy
Intervention:

Indicates status has not been verified in more than two years